; This proposal is a continuation of Project 2 in the original SPORE grant. Pertinent to this proposal, we have developed an anti-DRS monoclonal antibody therapy for pancreatic cancer through in vitro studies, animal model efficacy and with an industry partner (Daiichi Sankyo), Phase I and recently completed Phase II trials in pancreatic cancer. We have also discovered a novel molecule (DDX3) which appears to play a major role in regulation of anti-DRS mediated apoptosis. In this proposal, we will explore two strategies to enhance the efficacy of anti-DRS monoclonal therapy especially in pancreatic tumor cell lines which are intermediate or resistant to anti-DRS. The two strategies are to evaluate the addition of a monoclonal anti-DR4 reagent or the addition of small molecule modulators ofthe apoptosis cascade. The two apoptosis modulators to be evaluated are AT-101, a Bcl-2 family inhibitor, and AT-406, an lAP family inhibitor. These two strategies will be studied using in vitro analysis and orthotopic and metastatic xenogeneic pancreatic cancer models leading to a Phase I trial of the best strategy. In addition, we will continue studies of DDX3 and the DRS/DDX3 complex as a putative biomarker for tumor cell sensitivity/resistance to death receptor mediated anti-tumor efficacy and as the target of enhancement strategies for anti-DR mediated anti-tumor effects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101955-08
Application #
8375482
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
8
Fiscal Year
2012
Total Cost
$190,180
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Hwang, Chang-Il; Boj, Sylvia F; Clevers, Hans et al. (2016) Preclinical models of pancreatic ductal adenocarcinoma. J Pathol 238:197-204
Kim, Harrison; Samuel, Sharon; Lopez-Casas, Pedro et al. (2016) SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Mol Cancer Ther 15:680-8
Baker, Lindsey A; Tiriac, Hervé; Clevers, Hans et al. (2016) Modeling pancreatic cancer with organoids. Trends Cancer 2:176-190
Tzou, Ywh-Min; Bailey, Sarah K; Yuan, Kaiyu et al. (2016) Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer. Bioorg Med Chem Lett 26:1237-44
Biffi, G; Öhlund, D; Tuveson, D (2016) Building up the tension between the epithelial and stromal compartment in pancreatic ductal adenocarcinoma. Cell Death Differ 23:1265-6
Chio, Iok In Christine; Jafarnejad, Seyed Mehdi; Ponz-Sarvise, Mariano et al. (2016) NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer. Cell 166:963-76
Schultz, Matthew J; Holdbrooks, Andrew T; Chakraborty, Asmi et al. (2016) The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype. Cancer Res 76:3978-88
Nam, Ki-Hwan; Kim, Peter; Wood, David K et al. (2016) Multiscale Cues Drive Collective Cell Migration. Sci Rep 6:29749
Jones, Jacqueline; Mukherjee, Angana; Karanam, Balasubramanyam et al. (2016) African Americans with pancreatic ductal adenocarcinoma exhibit gender differences in Kaiso expression. Cancer Lett 380:513-22
Ho, Yen-Yi; Starr, Timothy K; LaRue, Rebecca S et al. (2016) Case-oriented pathways analysis in pancreatic adenocarcinoma using data from a sleeping beauty transposon mutagenesis screen. BMC Med Genomics 9:16

Showing the most recent 10 out of 152 publications